Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL2116737

O=C(O)c1ccc2cc(I)cc(-c3cccc4ccccc34)c2n1.[Li]

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 1/20 0.51
▸ KMT2A Q03164 3/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ MEN1 O00255 2/20 0.42
▸ MGAM O43451 1/20 0.41
▸ PIK3CA P42336 1/20 0.40
▸ ACMSD Q8TDX5 2/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ MMP2 P08253 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ GPR84 Q9NQS5 1/20 0.38
▸ LDHA P00338 1/20 0.38
▸ USP2 O75604 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ NR4A1 P22736 1/20 0.36
▸ NR4A2 P43354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118893 0.99 FDPS (0.52) FDPSKMT2AKDM4EMEN1MGAM
SCHEMBL2116734 0.97 FDPS (0.51) FDPSKMT2AKDM4EMEN1MGAM
Lithium Ion SCHEMBL2116736 0.86 FDPS (0.40) FDPSKMT2AKDM4EMEN1PIK3CA
SCHEMBL2117716 0.83 KDM4E (0.58) FDPSKMT2AKDM4EMEN1MGAM
SCHEMBL2118027 0.83 FDPS (0.57) FDPSKMT2AKDM4EMEN1MGAM
SCHEMBL2118134 0.83 FDPS (0.52) FDPSKMT2AKDM4EMEN1MGAM
SCHEMBL2117118 0.81 KMT2A (0.50) FDPSKMT2AKDM4EMEN1ALDH1A1
Lithium SCHEMBL2119069 0.78 FDPS (0.45) FDPSKMT2AKDM4EMEN1PIK3CA
SCHEMBL2116297 0.77 GPR84 (0.35) FDPSKMT2AKDM4EMEN1ACMSD
SCHEMBL13689572 0.77 NCF1 (0.39) FDPSKMT2AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094958-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2012-04-19 — — US claimed
CN-101959865-A Quinolines as farnesyl pyrophosphate synthase inhibitor NOVARTIS AG 2011-01-26 — — CN claimed
EP-2250152-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE Novartis AG (CH) 2010-11-17 — — EP claimed
WO-2009106586-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2009-09-03 — — WO claimed
US-20120094958-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2012-04-19 — — US disclosed
EP-2250152-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE Novartis AG (CH) 2010-11-17 — — EP disclosed
WO-2009106586-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2009-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094958-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE FDPS, GGPS1, CTPS1 FDPS 1/4885KMT2A 3963/4885KDM4E 2805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.